CUMBERLAND PHARMACEUTICALS (CPIX) Stock Fundamental Analysis
USA - NASDAQ:CPIX - US2307701092 - Common Stock
2.15 USD
+0.02 (+0.94%)
Overall CPIX gets a fundamental rating of 3 out of 10. We evaluated CPIX against 191 industry peers in the Pharmaceuticals industry. While CPIX seems to be doing ok healthwise, there are quite some concerns on its profitability. CPIX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CPIX was profitable.
In the past year CPIX had a positive cash flow from operations.
In the past 5 years CPIX always reported negative net income.
CPIX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -4.32%, CPIX is doing good in the industry, outperforming 71.73% of the companies in the same industry.
CPIX's Return On Equity of -10.47% is fine compared to the rest of the industry. CPIX outperforms 73.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -10.47% | ||
| ROIC | N/A |
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CPIX (83.99%) is better than 88.48% of its industry peers.
In the last couple of years the Gross Margin of CPIX has remained more or less at the same level.
CPIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
2. Health
2.1 Basic Checks
CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CPIX has been reduced compared to 1 year ago.
Compared to 5 years ago, CPIX has less shares outstanding
CPIX has a worse debt/assets ratio than last year.
2.2 Solvency
CPIX has an Altman-Z score of 0.60. This is a bad value and indicates that CPIX is not financially healthy and even has some risk of bankruptcy.
CPIX has a Altman-Z score of 0.60. This is comparable to the rest of the industry: CPIX outperforms 55.50% of its industry peers.
CPIX has a debt to FCF ratio of 0.75. This is a very positive value and a sign of high solvency as it would only need 0.75 years to pay back of all of its debts.
CPIX has a better Debt to FCF ratio (0.75) than 95.29% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that CPIX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.19, CPIX perfoms like the industry average, outperforming 46.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.75 | ||
| Altman-Z | 0.6 |
ROIC/WACCN/A
WACC8.26%
2.3 Liquidity
CPIX has a Current Ratio of 1.30. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.30, CPIX is doing worse than 75.39% of the companies in the same industry.
CPIX has a Quick Ratio of 1.17. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CPIX (1.17) is worse than 72.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.82% over the past year.
CPIX shows a decrease in Revenue. In the last year, the revenue decreased by -4.26%.
The Revenue has been growing slightly by 1.95% on average over the past years.
EPS 1Y (TTM)158.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-4.26%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%-8.8%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.50 indicates a rather expensive valuation of CPIX.
79.58% of the companies in the same industry are more expensive than CPIX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CPIX to the average of the S&P500 Index (26.06), we can say CPIX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.5 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CPIX is valued cheaper than 91.10% of the companies in the same industry.
CPIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPIX is cheaper than 95.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.63 | ||
| EV/EBITDA | 7.44 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CPIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CPIX (11/10/2025, 1:17:15 PM)
2.15
+0.02 (+0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners24.76%
Inst Owner Change0.03%
Ins Owners3.48%
Ins Owner Change0.01%
Market Cap32.16M
Revenue(TTM)37.87M
Net Income(TTM)-2.93M
Analysts43.33
Price TargetN/A
Short Float %0.61%
Short Ratio1.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.5 | ||
| Fwd PE | N/A | ||
| P/S | 0.76 | ||
| P/FCF | 4.63 | ||
| P/OCF | 4.52 | ||
| P/B | 1.15 | ||
| P/tB | 2.9 | ||
| EV/EBITDA | 7.44 |
EPS(TTM)0.1
EY4.65%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.46
FCFY21.58%
OCF(TTM)0.48
OCFY22.14%
SpS2.81
BVpS1.87
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.32% | ||
| ROE | -10.47% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.99% | ||
| FCFM | 16.5% |
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.75 | ||
| Debt/EBITDA | 1.85 | ||
| Cap/Depr | 3.11% | ||
| Cap/Sales | 0.43% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 251.96% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 0.6 |
F-Score7
WACC8.26%
ROIC/WACCN/A
Cap/Depr(3y)16.58%
Cap/Depr(5y)20.37%
Cap/Sales(3y)2.19%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.26%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%-8.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.42%
OCF growth 3YN/A
OCF growth 5YN/A
CUMBERLAND PHARMACEUTICALS / CPIX FAQ
Can you provide the ChartMill fundamental rating for CUMBERLAND PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 3 / 10 to CPIX.
What is the valuation status of CUMBERLAND PHARMACEUTICALS (CPIX) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUMBERLAND PHARMACEUTICALS (CPIX). This can be considered as Overvalued.
Can you provide the profitability details for CUMBERLAND PHARMACEUTICALS?
CUMBERLAND PHARMACEUTICALS (CPIX) has a profitability rating of 3 / 10.